230 related articles for article (PubMed ID: 38606465)
1. Interactions between Gepotidacin and
Oviatt AA; Gibson EG; Huang J; Mattern K; Neuman KC; Chan PF; Osheroff N
ACS Infect Dis; 2024 Apr; 10(4):1137-1151. PubMed ID: 38606465
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase.
Gibson EG; Bax B; Chan PF; Osheroff N
ACS Infect Dis; 2019 Apr; 5(4):570-581. PubMed ID: 30757898
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae.
Jacobsson S; Golparian D; Scangarella-Oman N; Unemo M
J Antimicrob Chemother; 2018 Aug; 73(8):2072-2077. PubMed ID: 29796611
[TBL] [Abstract][Full Text] [Related]
4. Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance.
Collins JA; Osheroff N
ACS Infect Dis; 2024 Apr; 10(4):1097-1115. PubMed ID: 38564341
[TBL] [Abstract][Full Text] [Related]
5.
Farrell DJ; Sader HS; Rhomberg PR; Scangarella-Oman NE; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069643
[TBL] [Abstract][Full Text] [Related]
6. Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.
Gibson EG; Oviatt AA; Cacho M; Neuman KC; Chan PF; Osheroff N
Biochemistry; 2019 Nov; 58(44):4447-4455. PubMed ID: 31617352
[TBL] [Abstract][Full Text] [Related]
7. Rapid Evolution of Reduced Susceptibility against a Balanced Dual-Targeting Antibiotic through Stepping-Stone Mutations.
Szili P; Draskovits G; Révész T; Bogár F; Balogh D; Martinek T; Daruka L; Spohn R; Vásárhelyi BM; Czikkely M; Kintses B; Grézal G; Ferenc G; Pál C; Nyerges Á
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235632
[TBL] [Abstract][Full Text] [Related]
8. Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections.
Scangarella-Oman NE; Hossain M; Hoover JL; Perry CR; Tiffany C; Barth A; Dumont EF
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0149221. PubMed ID: 34978887
[TBL] [Abstract][Full Text] [Related]
9. Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials.
Wagenlehner F; Perry CR; Hooton TM; Scangarella-Oman NE; Millns H; Powell M; Jarvis E; Dennison J; Sheets A; Butler D; Breton J; Janmohamed S
Lancet; 2024 Feb; 403(10428):741-755. PubMed ID: 38342126
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
[TBL] [Abstract][Full Text] [Related]
11. Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae.
Scangarella-Oman NE; Hossain M; Dixon PB; Ingraham K; Min S; Tiffany CA; Perry CR; Raychaudhuri A; Dumont EF; Huang J; Hook EW; Miller LA
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249694
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
Alt S; Mitchenall LA; Maxwell A; Heide L
J Antimicrob Chemother; 2011 Sep; 66(9):2061-9. PubMed ID: 21693461
[TBL] [Abstract][Full Text] [Related]
13. Intermethod comparability analyses of gepotidacin antimicrobial susceptibility tests using a large collection of globally collected Escherichia coli and Staphylococcus saprophyticus clinical isolates.
Arends SJR; Butler D; Scangarella-Oman N; Castanheira M; Mendes R
Diagn Microbiol Infect Dis; 2024 Mar; 108(3):116181. PubMed ID: 38215519
[TBL] [Abstract][Full Text] [Related]
14. Frequency of DNA gyrase and topoisomerase IV mutations and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran.
Azargun R; Soroush Barhaghi MH; Samadi Kafil H; Ahangar Oskouee M; Sadeghi V; Memar MY; Ghotaslou R
J Glob Antimicrob Resist; 2019 Jun; 17():39-43. PubMed ID: 30445211
[TBL] [Abstract][Full Text] [Related]
15. A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with
Morgan H; Lipka-Lloyd M; Warren AJ; Hughes N; Holmes J; Burton NP; Mahenthiralingam E; Bax BD
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675148
[TBL] [Abstract][Full Text] [Related]
16. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
Cambau E; Matrat S; Pan XS; Roth Dit Bettoni R; Corbel C; Aubry A; Lascols C; Driot JY; Fisher LM
J Antimicrob Chemother; 2009 Mar; 63(3):443-50. PubMed ID: 19147516
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV.
Hofny HA; Mohamed MFA; Gomaa HAM; Abdel-Aziz SA; Youssif BGM; El-Koussi NA; Aboraia AS
Bioorg Chem; 2021 Jul; 112():104920. PubMed ID: 33910078
[TBL] [Abstract][Full Text] [Related]
18. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
19. Target-Mediated Fluoroquinolone Resistance in
Collins JA; Oviatt AA; Chan PF; Osheroff N
ACS Infect Dis; 2024 Apr; 10(4):1351-1360. PubMed ID: 38606464
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
